AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 201 min read$RCKT

Shah Gaurav sold $8K of RCKT

Shah Gaurav (CEO) sold 2,293 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.38 on 2026-08-18.

Original reporting
SEC EDGAR · Shah Gaurav
Published Aug 20, 2026, 9:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RCKT
Neutral
high confidence
Mentioned
$RCKT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The sale represents less than 0.2% of the CEO's holdings and is unlikely to affect stock price.

02

Market read

Low relevance; routine insider transaction with minimal trading implications.

03

What to watch

Potential upcoming corporate actions not disclosed.

Relevance 3/10Novelty 3/10Timing: filed on 2026-08-20

Background

Form 4 filings disclose insider transactions; this one reports a modest CEO share sale.

Company-level read

Ticker impact

$RCKTNeutralHigh confidence
Context

CEO Shah Gaurav sold 2,293 shares for $7,752.63 in a Form 4 filing.

Expected impact

Likely negligible price movement.

Evidence & confidence

The transaction size is tiny relative to total holdings and market cap.

Market effects

Sector

No significant effect on the biotech sector.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even small insider sales can signal concerns, but size here is trivial.

Key entities

  • Company
    Rocket Pharmaceuticals, Inc.

    Biotech firm listed on NASDAQ under ticker RCKT.

  • Person
    Shah Gaurav

    CEO of Rocket Pharmaceuticals.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCKT insider trading history →

Related articles

OCT 8
$RCKTMed

Goldman Sachs Upgrades Rocket Pharmaceuticals (RCKT) to Neutral

Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral, citing encouraging clinical updates on its gene therapy candidate RP-A501. The company remains unprofitable with no revenue, but its market cap of $284M reflects growth expectations. RCKT's GF Score is 35/100, showing mixed fundamentals. Insiders have sold shares, while some institutional investors hold positions.

gurufocus.com5 min
OCT 8
$RCKTHigh

Why is Rocket Pharmaceuticals stock up 3% today?

Rocket Pharmaceuticals (RCKT) rose 2.8% after Goldman Sachs upgraded it to Neutral with a $4.00 price target, citing positive clinical data for RP-A501. Other analysts maintained bullish ratings, while some lowered targets due to long timelines. The company secured a $150M credit facility. The move was company-specific, as broader markets were down.

investing.com2 min
OCT 8
$RCKTMedAI 8/10

Rocket Pharmaceuticals bags $150 million as it pushes pivotal Danon disease study

Rocket Pharmaceuticals secured up to $150 million in financing from Hercules Capital, including an initial $35 million. The funds will support a pivotal Phase 2 study for its gene therapy candidate RP-A501 for Danon disease and broader cardiovascular pipeline development. The company reported $283.7 million in cash as of June 30, 2026, and expects the financing to extend its cash runway.

indianpharmapost.com2 min